<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042557</url>
  </required_header>
  <id_info>
    <org_study_id>NCC202062402</org_study_id>
    <nct_id>NCT05042557</nct_id>
  </id_info>
  <brief_title>Real World Study of MPM in China</brief_title>
  <official_title>Real World Study of Diagnosis, Treatment and Prognosis of Malignant Pleural Mesothelioma in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with atypical clinical&#xD;
      manifestations. Most patients with MPM are at an advanced stage at the time of diagnosis, and&#xD;
      only a few patients can be cured by radical surgery and other treatment measures. Pemetrexed&#xD;
      + cisplatin chemotherapy with or without bevacizumab is still the standard treatment for MPM.&#xD;
      In recent years, multimodality therapy including surgery, radiotherapy and chemotherapy have&#xD;
      shown certain advantages in improving patient overall survival time. Targeted and&#xD;
      immunotherapy may bring breakthroughs in MPM therapy. However, there are still no&#xD;
      high-quality evidence-based medical evidence reports on the treatment model and effects of&#xD;
      MPM patients in China.&#xD;
&#xD;
      Focusing on MPM, we plan to systematically review the relevant scientific literature, confirm&#xD;
      relevant scientific research questions, and provide references for related treatments. On&#xD;
      this basis, we will estimate MPM incidence and mortality rates from 2014 to 2025 based on the&#xD;
      data published by the National Cancer Registry. Meanwhile, a retrospective study cohort was&#xD;
      constructed based on the electronic medical record database, and according to the research&#xD;
      demand, patients were followed up with their post-discharge survival status to&#xD;
      comprehensively describe and analyze the incidence, diagnosis, treatment, and prognosis of&#xD;
      MPM patients. Also, exploratory analysis of the therapeutic effects of existing clinical&#xD;
      treatments was conducted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year overall survival</time_frame>
    <description>Overall survival is defined as the time from diagnosis to death for any reason or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-year progression-free survival</time_frame>
    <description>Progression-free survival is defined as the time from diagnosis to the first event of progression</description>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Diagnoses Disease</condition>
  <condition>Treatments</condition>
  <condition>Prognosis</condition>
  <arm_group>
    <arm_group_label>Sun Yat-sen University Cancer Center</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>hanghai Chest Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Tianjin Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fudan University Shanghai Cancer Center</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Anhui Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Shandong Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hunan Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Yunnan Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese Academy of Medical Sciences</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were pathologically confirmed as malignant pleural mesothelioma is included in&#xD;
        this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed as malignant pleural mesothelioma&#xD;
&#xD;
          -  Aged over 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Follow-up less than 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zhouguang Hui, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhouguang Hui, Ph.D.</last_name>
    <phone>861067781331</phone>
    <email>drhuizg@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhouguang Hui, M.D.</last_name>
      <phone>8610-87787230</phone>
      <email>drhuizg@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhouguang Hui, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zhouguang Hui, M.D.</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>MPM</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

